Autoantibodies to five aminoacyl-tRNA synthetases have been reported, and all have been associated with a syndrome of myositis and interstitial lung disease. Four of these synthetases exist free in the cytoplasm, but the fifth, isoleucyl-tRNA synthetase (recognized by anti-OJ autoantibodies), is a component of the multi-enzyme complex containing at least seven synthetases. In an effort to better understand the origins of these antibodies, we examined sera from 11 patients with anti-OJ autoantibodies for evidence of reaction with other components of the complex. All sera showed a characteristic pattern of 10 protein bands by immunoprecipitation from HeLa cell extract. 10 of 11 sera significantly inhibited isoleucyl-tRNA synthetase enzyme activity. Serum and IgG from four patients also inhibited leucyl-tRNA synthetase activity, and serum and IgG from two inhibited lysyl-tRNA synthetase. Immunoblotting experiments supported reaction of the two sera with lysyltRNA synthetase, and revealed additional reactivity of three sera with a 160-kD component believed to be glutaminyl-tRNA synthetase. Despite reaction of some sera with additional synthetases, the immunoprecipitated tRNA appeared the same with all sera, and functioned as tRNAi'e.
Introduction
Autoantibodies to aminoacyl-tRNA synthetases have been closely associated with the autoimmune inflammatory myopa-thies, polymyositis (PM)' and dermatomyositis (DM) (1) (2) (3) (4) (5) (6) (7) (8) , occurring in -25-30% of PM/DM patients. They include anti-Jo-1, the most common (9) , which reacts with histidyltRNA synthetase (HisRS) (10); anti-PL-7, which reacts with threonyl-tRNA synthetase (3, 4) ; anti-PL-12 with alanyltRNA synthetase and tRNAala (2, 6) ; anti-EJ with glycyltRNA synthetase (5, 1 1 ); and anti-OJ with isoleucyl-tRNA synthetase (HeRS) (5) . The autoantibodies to aminoacyltRNA synthetases (antisynthetases) have been associated with a characteristic clinical picture, marked by a high frequency of interstitial lung disease (ILD; 50-75% of patients [ 1, 12, 13 ]), arthritis ( 14) , Raynaud's phenomenon, fevers, and other features, that has been referred to as the "antisynthetase syndrome" ( 1-4, 6, 11-14) . Despite the similarity in the associated clinical picture between patients with different antisynthetases, no individual patient has previously been reported to have autoantibodies to more than one aminoacyl-tRNA synthetase enzyme.
Anti-OJ antibody was originally identified when the two original sera from patients OJ and NJ were found to immunoprecipitate identical tRNA and protein bands from HeLa cell extract. Serum and IgG from these patients strongly and specifically inhibited the enzymatic activity of IleRS, which catalyzes the formation of Ile-tRNA from Ile and tRNAiIC (5) . In higher eukaryotic cells, 7-9 ofthe 20 synthetases (those for glutamine, isoleucine, leucine, methionine, glutamic acid, arginine, lysine, and sometimes aspartic acid and/or proline) are found together in a stable, high molecular weight complex along with three other nonsynthetase proteins ( 15, 16) . Almost all of the enzymatic activity of IleRS is found associated with this multienzyme complex. The other four synthetases against which human autoantibodies have been identified are usually found free in the cytoplasm, and they are not found in purified complexes. The 10 protein bands immunoprecipitated by OJ and NJ sera were consistent in molecular weight with those ofthe multi-enzyme complex (5) .
Using sera from 11 patients that contained anti-OJ autoantibodies as determined by immunoprecipitation (IP) of the synthetase complex pattern, we addressed the questions ofwhether all anti-OJ sera react with the same component of the synthetase complex, and whether any react with multiple components. Our findings revealed a complicated picture that may provide important insights into the mechanisms for the development ofantisynthetases in particular and other autoantibodies to ribonucleoprotein complexes generally.
Methods
Sera. Sera from > 1,000 patients were tested by IP, including sera from patients with proven or suspected myositis from clinics at the University of Oklahoma Health Sciences Center or the National Institute for Arthritis, Musculoskeletal and Skin Diseases; sera referred from other centers; and sera with anticytoplasmic antibodies by indirect immunofluorescence even if there was no suspicion of myositis. Many of the patients had been included in previous studies (4-6, 12, 17, 18) . Those showing the anti-OJ pattern were identified. "Original anti-OJ sera" refers to the two sera from patients described in the previous study of anti-OJ (NJ and OJ) (5) . Two sera with anti-OJ (RH and GZ) that had been included in a large study of myositis ( 12) were included here with the "new" sera since immunological analysis had not previously been described. Two other samples with anti-OJ were excluded because the patient of origin could not be confirmed.
Immunoprecipitation. IPs for protein and nucleic acid analyses were performed as previously described (5 (5) or immunoprecipitate ofanti-OJ sera from HeLa cell extract. The procedure for immunoblotting using whole extract was as previously described ( 19) with the following modifications. After 8-9% SDS-PAGE and transfer to nitrocellulose, strips were blocked with 5% bovine nonfat milk in Tris-saline blotting buffer. Sera were diluted 1:100 in this milk solution. Goat anti-human IgG/alkaline phosphatase was used as conjugate and bromo-chloro-indolyl-phosphate/nitroblue tetrazolium as substrate (Kierkegaard & Perry Laboratories, Gaithersburg, MD).
Immunoblotting of immunoprecipitates was performed to determine whether immunoblot bands represented complex components. IP was performed using unlabeled cells prepared as above for nucleic acid IP, but the quantities ofserum, cells, and Sepharose were increased fourfold per sample. Immunoprecipitates were electrophoresed and transferred to nitrocellulose, strips were developed as for immunoblot, but were blocked overnight, and a protein A/ alkaline phosphatase conjugate was used. To determine which IP bands were recognized in immunoblot, 35S-labeled extract was used for IP, and an autoradiograph of the nitrocellulose was taken after transfer. The portion of the nitrocellulose above the 60-kD molecular mass level was developed as above for immunoblotting. The nitrocellulose strips were positioned as in the original sheet, and then overlaid with the autoradiograph.
Antibody was affinity-purified from immunoblots by identifying and excising the band ofinterest, blocking, incubating with sera diluted 1:100, and washing as for immunoblotting. Specific antibody was eluted by incubation for 2 min at 4°C in 0.2 M glycine buffer, pH 2.8, with 0. 15 M NaCl and 0.05% Tween 20, followed by immediate neutralization with 1 M Tris. The entire 0.5 ml eluate containing affinity-purified antibody was then used for immunoprecipitation or was mixed with 0.125 ml of 20% milk and used for immunoblotting. In some cases, 3 M Na thiocyanate was used for elution and removed with dialysis.
Aminoacylation inhibition. Each aminoacyl-tRNA synthetase catalyzes an aminoacylation reaction (tRNA charging) in which its particular amino acid is covalently linked to the cognate tRNA. The ability of sera to inhibit the activity of each synthetase was tested individually as described previously (5, 19 calf liver extract. The enzyme source was preincubated with patient or control serum, usually diluted 1:10. Activity was tested at 10 and 20 min as the radioactivity incorporated into the trichloroacetic acid precipitate. The percentage of inhibition = [(activity with normal sera -activity with patient sera) .-(activity with normal sera)] X 100. As a result of nonspecific inhibition by some sera, and as determined by previous studies, inhibition by a serum was considered significant only if > 50% of activity was inhibited as compared with the average results with at least two normal sera. For confirmation of significant inhibition, purified IgG was obtained by DEAE chromatography as described previously (5, 19) .
To determine the identity of the immunoprecipitated tRNA, IP reactions using OJ serum were performed as described above until sufficient tRNA was obtained. The tRNA was isolated by phenol extraction and ethanol precipitation, and used in a standard aminoacylation reaction. The immunoprecipitated tRNA was tested for the ability to accept each of the amino acids whose synthetase is consistently found in the multi-enzyme complex except arginine, which was unavailable in labeled form at the time of this portion of the study. Results were standardized on a molar basis (picomoles of amino acid incorporated into the precipitate) and standardized between experiments by comparison to charging with isoleucine.
Results

Autoantibody identifcation
IP with sera from nine new patients showed a protein pattern that was identical to that of sera from the original two anti-OJ patients (Fig. 1) . Since the pattern was composed of 10 consistent bands (Fig. 1, a- The nine new sera that immunoprecipitated the protein pattern all immunoprecipitated tRNA bands from HeLa cells that appeared identical to those of the original two sera, consisting of one faster migrating, more intense band and one weaker band (Fig. 2) . A third weak, fast migrating band that may have been a degradation product was seen in some experiments. The pattern could be distinguished from the tRNA bands seen with other antisynthetases (Fig. 2) . The combination of protein and nucleic acid bands by IP confirmed the anti-OJ antibody specificity. The Ro/SSA RNAs were seen with sera RH and RB, the La/SSB RNAs with serum RH, the U 1 RNA and an unidentified 7S RNA with JM, and an unidentified 4.5-S RNA similar in migration to the Mas RNA with JX (12 (5) . No anti-OJ serum showed consistent significant inhibition of synthetases for the other 14 amino acids that are not shown. * All results shown for this patient are for follow-up serum. The initial sample, which had much stronger anti-OJ activity by IP, was depleted, but had inhibited IleRS 81 % and LeuRS 60-81 % in previous studies. * All tests for RB, all for WH except Gln, and all for GZ-IgG, were performed separately; 10-min readings are shown.
§ Serum was depleted; tested previously (5). 10-min readings (others are 20-min readings). 'Follow-up serum, which had reduced anti-IleRS activity compared with original serum, was used for this test because initial serum was depleted. ** RB-IgG showed 41% inhibition (not significant).
by JX. In addition, staining related to coexisting antibodies to Ro/SSA, La/SSB, and U1RNP was seen, as expected from the IP results.
The molecular masses suggested that the 160-, 150-, and 140-kD bands might have been bands a, b, and c, respectively, of the complex. The 48-kD band was closest in size to band h, but migrated faster. Two approaches were taken to determine whether these bands were components of the synthetase complex: (a) affinity purification ofantibodies to each ofthe bands, and (b) immunoblotting of the immunoprecipitated synthetase complex.
Affinity-purified autoantibodies. Affinity-purified autoantibodies to the proteins of 160 kD (from NJ and AC), 150 kD (from JS), 140 kD (from GZ), and 48 kD (from OJ, JS, and GZ) were obtained by elution from immunoblots and tested in immunoprecipitation (Fig. 4) . In each case, the presence of active antibody without other significant bands was confirmed by restaining in immunoblot (not shown). Anti-OJ proteins a, b, and c were visible in immunoprecipitates of affinity-purified anti-1 60-kD antibodies. However, the bands were very weak despite intense staining by these antibodies in immunoblot. Affinity-purified anti-1 50-kD from JS serum also immunoprecipitated anti-OJ-associated proteins, and the protein bands were much more intense than with anti-160 kD. The a, b, and c proteins were also seen with affinity-purified anti-48 kD from JS serum, but they were not as strong as with anti-150 kD ofJS serum, and they were not seen with anti-48 kD of OJ, GZ, or NJ sera. The reason for this difference in results with anti-48 kD from different sera was unclear.
Affinity-purified anti-140-kD antibodies did not show IP of anti-OJ-associated proteins. None of the affinity-purified antibodies showed detectable tRNA on IP. These data suggested that the 160-and 1 50-kD immunoblot bands were components of the synthetase complex and that the 140-kD band was not. This method could not demonstrate definitively which synthetase complex components corresponded to the 160-and 1 50-kD bands. Immunoblotting of immunoprecipitated complexes. When immunoprecipitates obtained using serum RH were used as antigen source for immunoblotting, the 160-kD band was detected with JH and AC sera (latter not shown), and the 1 50-kD band was identified by JS serum (Fig. 5) By comparison with protein-stained immunoprecipitates, the 1 60-kD band corresponded in size to band a and the 150-kD band to band b. The identity ofband a in the human synthetase complex is not settled, but glutaminyl-tRNA synthetase (20, 21 ) or a multifunctional synthetase showing both glutamyl-tRNA synthetase and prolyl-tRNA synthetase activity (22) have been proposed. Protein band b appears to be IleRS, as determined by molecular mass ( 140-150 kD for IleRS) and position in the complex ( 15, 20) . The 140-kD protein band was of slightly higher molecular weight than band c, consistent with the other evidence that it was not part of the synthetase complex. The 75-kD band of sera JH and RB corresponded to bandf, which appears to be LysRS, consistent with the aminoacylation inhibition data. Of note was that band f was more intense in 35S-immunoprecipitation with JH and RB sera than with other sera (see Fig. 1 Table II. Identification ofimmunoprecipitated tRNA Immunoprecipitated tRNA prepared using standard OJ serum was tested for acceptor activity for each of the amino acids except arginine whose synthetase is consistently associated with the multi-enzyme complex (see Methods). Aspartic acid, which has been found in the complex in some studies, was also tested. Fivefold more isoleucine on a molar basis was accepted by immunoprecipitated tRNA than the next closest amino acid, glutamic acid (Fig. 6 ). Of particular significance, however, was the finding that some sera reacted with more than one component of the complex. This demonstrates additional antisynthetase activity in myositis beyond the five synthetases known to be autoantigens, and provides the only instance in which individual patient sera reacted with more than one synthetase. In addition to autoantibodies against IleRS, anti-OJ sera with autoantibodies to LysRS and the 1 60-kD synthetase protein were demonstrated, and evidence of antibodies to LeuRS and possibly to arginyltRNA synthetase was seen. Serum JH appeared to have activity against four different synthetases, while RB and AC may have reacted with three.
Clinical features
The most convincing evidence was for reaction of JH and RB sera with LysRS, because aminoacylation inhibition data were confirmed by immunoblotting data. RB also showed both inhibition and immunoblotting of arginyl-tRNA synthetase, but inhibition could not be confirmed at the > 50% level with purified IgG. The very strong reaction with LysRS raises the possibility that LysRS, rather than IleRS, was the primary antigen for these sera. Against this, however, was the fact that the tRNA pattern was unchanged.
Three sera reacted in immunoblot with the highest molecular weight component of the synthetase complex ( 160 kD). Studies of the cDNA sequence coding for the largest component (reported as 170 kD) noted homology with bacterial glutaminyl-tRNA synthetase and assigned the identity of glutaminyl-tRNA synthetase to the protein on that basis (20, 21 ) . However, previous studies of the complex in other mammals identified the highest molecular weight component as glutamyl-tRNA synthetase ( 15 ) . Later, prolyl-tRNA synthetase activity was also associated with this band ( 15) . A recent study in which cDNAs coding for portions of the homologous protein ( 190 kD) ofDrosophila were expressed in Escherichia coli showed that the amino-terminal portion of the protein had glutamyl-tRNA synthetase activity, while the carboxy-terminal portion had prolyl-tRNA synthetase activity (22) . Anti-160 kD in anti-OJ sera apparently did not inhibit 1 60-kD enzymatic activity, since the three sera did not significantly inhibit glutaminyl-tRNA synthetase, glutamyl-tRNA synthetase, or prolyl-tRNA synthetase. Anti-160 kD differed in this way from other autoantibodies to synthetases, but resembled antisera of animals immunized with synthetases, which often do not inhibit the synthetase's activity (24, 25 (Fig. 5 ). This suggests exclusive reactivity with conformational epitopes and not linear epitopes ofthe antigens. Exclusive reactivity with conformational epitopes, with negative immunoblots, although unusual in general, has been seen with other myositis-specific autoantibodies, including anti-PL-7 (26), anti-Mi-2 (17), and anti-Fer (27) . Although most anti-Jo-1 sera react by immunoblot ( 18) , this is not due to reaction with short linear epitopes. Anti-Jo-1 autoantibodies did not react when tested against each of the hexapeptides that could be derived from the entire sequence of the HisRS molecule, while animal antisera reacted with many peptides throughout the protein (24) .
Thus, patients may develop autoantibodies to multiple synthetases that are components of the synthetase complex, but not to synthetases outside the complex. Sera with autoantibodies to synthetases that are not in the complex never have autoantibodies to more than one synthetase. A possible explanation is that the primary anti-OJ response is directed at IleRS, and this initial response renders the entire synthetase complex immunogenic, perhaps as a result of immunization with altered complexes containing bound anti-IleRS. This is similar to the hypothesis proposed to explain a response against multiple epitopes resulting from molecular mimicry at a single epitope (28) . Extension ofan initial immune response against one component to other components ofa macromolecular complex has been observed in serial samples from patients with anti-U 1 RNP and anti-Sm (29) , and may be the mechanism for autoantibodies to multiple components of other complexes. The formation ofanti-160 kD, anti-LeuRS, and anti-LysRS as extensions rather than primary responses may explain the inability to demonstrate immunoprecipitated tRNA, and the lack of inhibition of 160 kD. Extension may be more like a conventional immunization than is the primary antisynthetase response. The mechanism for the primary antisynthetase response is a central question.
The three highest molecular weight components appeared to be the most abundant proteins of the immunoprecipitated synthetase complex in all immunoprecipitation gels. Although this could have resulted from higher methionine content, these bands were also stronger by protein stain of immunoprecipitates (Fig. 5 ). These components ( 160 kD [a], IleRS [b] , and LeuRS [c]) are not known to be overrepresented in the complex (15) . A possible explanation is that trimolecular complexes of proteins a, b, and c may exist, in addition to the full multi-enzyme complexes. Autoantibodies to one component of the trimolecular complex would immunoprecipitate both it and the full complex. A partial complex might be generated in vitro during extract preparation, or could be present in vivo. In the above hypothesis, such in vivo partial complexes could also be immunogenic after a response to IleRS, consistent with our evidence of autoantibodies to each of the three components.
The data do not exclude the possibility of reaction of anti-OJ sera with additional synthetase complex components. It is possible that additional autoantibodies reactive with synthetase complex components exist that neither inhibit synthetase activity nor react by immunoblot, and were not detected. There may even be a synthetase other than IleRS that is bound by all anti-OJ sera. Even if such antibodies existed, however, the anti-IleRS would still be the most likely primary response. All four other primary antisynthetase antibody responses inhibit enzymatic activity and immunoprecipitate tRNA, properties shared by anti-IleRS; if undetected autoantibodies existed, they would have neither property. Such undetected autoantibodies should still be capable of immunoprecipitating the synthetase complex, and thus we can exclude their existence in anti-OJ-negative sera.
Although anti-OJ autoantibodies are uncommon, their unique features may provide important insights into mechanisms leading to the induction and maintenance of autoantibodies generally. These findings support the hypothesis that the responses are antigen driven, and provide an example of autoantibodies to multiple components of a macromolecular complex, which may have developed after a primary response against a single component. The studies demonstrate for the first time sera reactive with multiple synthetases, but when the details of their reactivity are considered, this is consistent with previous impressions about the independence of the five individual primary antisynthetase autoantibody responses.
